Compare · KAPA vs NVO
KAPA vs NVO
Side-by-side comparison of Kairos Pharma Ltd. (KAPA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KAPA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $172.11B, about 79375.9x KAPA ($2.2M).
- NVO has been more active in the news (9 items in the past 4 weeks vs 5 for KAPA).
- NVO has more recent analyst coverage (25 ratings vs 0 for KAPA).
- Company
- Kairos Pharma Ltd.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $2.2M
- $172.11B
- 1M return
- -
- -0.41%
- 1Y return
- -
- -20.64%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- 2024
- News (4w)
- 5
- 9
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest KAPA
- SEC Form 10-Q filed by Kairos Pharma Ltd.
- Kairos Pharma Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology
- Kairos Pharma Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Kairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development
- SEC Form 8-K filed by Kairos Pharma Ltd.
- Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
- Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
- Kairos Pharma Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S